BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:BioE COLLOQUIA SERIES:  "Fighting Cancer With Spider Silk and Othe
 r Nanoparticles"
DTSTART:20190930T121500
DTSTAMP:20260429T153356Z
UID:8286120939942f6f7626f8d0746edaf15253960a634c9ba21b848564
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Carole Bourquin\, University of Geneva\, CH\nWEEKLY BIOE
 NGINEERING COLLOQUIA SERIES\n(sandwiches served)\n\nAbout the talk: \nCaro
 le Bourquin and her group focus on novel bioinspired strategies for the ta
 rgeting of the immune system to treat cancer. The group investigates how n
 anoparticles of different types can be used to mimic bacteria or viruses i
 n order to trigger immunity in cancer patients. The nanoparticles are firs
 t screened for potential toxicity or functional effects on immune cells. T
 hey are then loaded with immune-modulating drugs and selected for their ca
 pacity to trigger immune responses. Finally\, their potential to block tum
 or growth is examined. Prof. Bourquin will describe how bioengineered part
 icles made from spider silk can serve as vaccine\, and how gold nanopartic
 les can impact immune responses.\n\nReferences:\n\n	Mottas I.\; et al\, Am
 phiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7
  ligand via local immune activation\, Biomaterials\, 2019\n	Lucke M.\, et 
 al.\, Engineered hybrid spider silk particles as delivery system for pepti
 de vaccines\, Biomaterials\, 2018\n	Hočevar S\, et al. Polymer-Coated Gol
 d Nanospheres Do Not Impair the Innate Immune Function of Human B Lymphocy
 tes in Vitro\, ACS Nano. 2019\n\n\nBio:\nCarole Bourquin studied medicine 
 in Geneva\, Switzerland\, then moved to the Max-Planck Institute of Neuroi
 mmunology in Munich to perform her PhD. She set up her own research group 
 in cancer immunotherapy at the Division of Clinical Pharmacology in Munich
  and at the same time headed the clinical consultations of the division. I
 n 2011\, she returned to Switzerland as full professor of pharmacology at 
 the University of Fribourg\, where she joined the NCCR Bioinspired Nanomat
 erials from 2014 to 2018. There\, she developed highly productive collabor
 ations to study novel nanomaterial-based delivery systems for immunotherap
 y. In addition\, she built and headed the Unit of Clinical Pharmacology at
  the Fribourg Cantonal Hospital\, and was president of the hospital drug c
 ommission. Since August 2016\, Carole Bourquin is full professor of pharma
 cology at the University of Geneva. Her pioneering research in immuno-onco
 logy is supported by the Swiss National Science Foundation\, Oncosuisse an
 d the European research program Horizon 2020. She is a member of several s
 cientific networks\, including the European training network IMMUTRAIN.\n\
 nZoom link for attending remotely: https://epfl.zoom.us/j/941417884
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR